Enlivex Therapeutics (ENLV) Set to Release Quarterly Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to be releasing its results on Friday, November 13th. Analysts expect the company to post earnings of ($4.48) per share for the quarter.

Enlivex Therapeutics Trading Up 5.0%

NASDAQ ENLV opened at $1.26 on Thursday. Enlivex Therapeutics has a 12 month low of $1.18 and a 12 month high of $434.40. The stock has a 50-day simple moving average of $7.13 and a 200 day simple moving average of $130.20.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ENLV shares. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4,800.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.